

Parkinson's disease (PD)



Professor Dr Sinaa A. Kadhim

M.B.Ch.B, GP.Rad., MSc., PhD.Pharm

:Objectives

know drugs used in patients with Parkinson -1
.disease

.know mechanism of action of each drug -2

know side effects, interaction, indication and -3
.contraindications



:Dopamine agonists: 2 types .2

Ergot alkaloids -1

Non - ergot alkaloids-2

:Ergot alkaloids -1


A- Bromocriptine: acts as

Partial agonist on D2 receptor in the brain -1

.Some **alpha 1 antagonist** effect -2

It increases the activity of dopamine neurotransmitter

B- Pergolide / cabregoline: act by activation of dopamine
.receptors (**D1 and D2**)



: Clinical use

They are used in

:A- Parkinson disease as

.Individual drugs -1

.Combined with levodopa -2

.End-of-dose deterioration of l-dopa -3

.Intolerant to levodopa -4

B- Hyperprolactinemia

:Kinetics**

**Bromocriptine is metabolized by cytochrome P450 3A4 , excreted
.primarily in the feces via biliary secretion**

**Parent drug and metabolites are almost completely excreted via the
.liver, and only 6% eliminated via the kidney**

:Side effects

CVS: cardiac arrhythmias and postural hypotension(vasodilatation.....)

.....Dyskinesias

Behavioral: hallucination, confusion and delusion...
(occur more than with L-dopa)

GIT : anorexia, nausea, and vomiting

:Contraindication

Psychosis (psychiatric problem)-

The ergot-derived agonists are **best avoided** in patients with-
.peripheral vascular disease (bs ergot cause Erthromelalgia)

:Ergot relates side effects

Pulmonary infiltrates -1

:NOTE (for your informations)

a **pulmonary infiltrate** is a substance denser than air than air, such as pus than ,as pus, blood or protein, which lingers within the parenchyma of the lungs. can be observed on a chest radiograph



Erthromelalgia -2

:NOTE (for your informations)

Erythromelalgia is a disorder in which blood vessels are episodically blocked (frequently on and off daily) then become hyperemic and inflamed with pain



:Non-ergot derivatives -2

pramipexole (preferential affinity for **D3 R**), **agonist**, less mental S/E, **excreted unchanged in the urine** (dosage **adjustments** are needed in renal dysfunction)

ropinirole (pure **D2** agonist), **more serious S/E**. (The **exact mechanism** of action of **ropinirole** as a treatment for Parkinson's disease is **unknown**)

They are considered to be **first line** drugs in the **initial management** of Parkinsonism

Rotigotine : **non selective** dopamine R agonist with **more** selectivity to **D3 R**, given as a patch or injection

Apomorphin : A **short-acting injectable** dopamine agonist temporary relief **off period** of akinesia, act on **D₂-like** and, to a much **lesser extent, D₁-like** receptors. It also acts as an **antagonist** of **5-HT₂** and **α-adrenergic receptors** with high affinity

Side effects: include

Postural hypotension

Dyskinesias

Fatigue

.Drowsiness and Sleepiness (should be taken at night)

Wt. gain (bs dopamine induce compulsive over eating)

Emesis(stimulation of CTZ induce vomiting)

:Clinical uses

a-Parkinsonism

b-Restlessness leg syndrome(RLS) {for your information: an unpleasant feeling when going to sleep and a **strong urge to move**. The movement makes it .hard or impossible to get enough sleep}

. **c-Apomorphine** is used also in : **1-anxiety** **2-emetic (to induce vomiting)**

.treating erectile dysfunction-**3**

: Drug interaction

Antipsychotics (like chlorpromazine, haloperidol which block D2 R)-
Metoclopramide (D2 antagonist)-
Sleep producing drug (diazepam)-
other CNS suppressant drugs like opiod and antihistamine-
**Cimetidine and The fluoroquinolone antibiotics and other--
inhibitors of CYP450 1A2 isoenzyme** (for example, fluvoxamine)
may inhibit the metabolism of ropinirole, requiring an **adjustment**
.in ropinirole dosage

:Contraindications

,History of **psychotic** illness 2- Recent **myocardial infarction** -1
.Active peptic **ulceration** -3



:Amantadine .3

:Is an antiviral drug. It enhances Dopamine activity by

Increasing synthesis and release of dopamine or-1

.Inhibition of reuptake of dopamine-2

.Muscarinic blocking actions -3

.inhibiting the N-methyl-D-aspartate (NMDA) type of glutamate recept-4

Side effects include

,**Behavioral**: restlessness-

hallucination, agitation

,**Urinary** effects: retention-

(anti cholinergic effects)

GIT : nausea and vomiting-

Postural hypotension-

Dermatological reactions-


include livedo reticularis

What Is An Anticholinergic Agent?

An anticholinergic agent is a substance that inhibits the parasympathetic nerve impulses by selectively blocking the binding of the neurotransmitter **acetylcholine** to its receptor in nerve cells.

Anticholinergics help treat overactive bladder by affecting the nerve function of the **bladder muscle (detrusor)** to relax.

Helps reduce urinary urgency.



:NOTE (for your informations)

Livedo reticularis is a lace-like purplish discoloration of the skin caused by swelling of the venules owing to obstruction of capillaries .by small blood clots

As shown in the following picture



Figure 1. Reticulated brownish gray discoloration accompanied by pale areas indicating livedo reticularis.

Selegiline, rasagiline and safinamide .4

Are **selective** inhibitors **MAO-B** (the enzyme that metabolizes dopamine to nor epinephrine and serotonin in brain)


It **enhance** l-dopa effect(allowing the **dose** of levodopa to be **reduced**)
. (and may **reduce on-off** or wearing-off phenomena

at **low to moderate** doses they **not** inhibit **MAO** Type **A** (which metabolizes dopamine, norepinephrine and serotonin). But in **high** doses they **loses** thier **selectivity** (inhibit .both MAO- A and B)

Selegiline is metabolized to **methamphetamine** and amphetamine,
(whose stimulating properties may produce **insomnia** if the drug is
. (administered later than mid-afternoon

Rasagiline(**irreversible inhibitor of MAO B**, is **more potent** than selegiline in preventing MPTP(drug induce parkinsonism), not ,metabolized to an amphetamine-like substance (**NO insomnia**)
. and is being used for **early treatment** in patients with **mild** symptoms

▶ dopamine
■ selegiline



Levels of
dopamine
increase

Dopamine

MAO B



Selegiline

Metabolites



Contraindication: with

Mepridine-1

.Selective serotonin reuptake inhibitors-2

severe liver impairment -3

:Side effects

GIT: Nausea and vomiting

CNS: Confusion, visual hallucinations, dizziness, headache, and
.insomnia, especially at higher doses

Psychiatric: The **combined** use of these agents at **high doses** with
.l-dopa **results** in an increased incidence of **dyskinesia** and psychosis

CVS: Postural hypotension



:Inhibitor of COMT-5

.Intacapone and Tolcapone

COMT is the enzyme that converts levo Dopa to 3-O-methyl dopa
(3OMD)

.These drugs **selectively** and **irreversibly** inhibit COMT

Increased 3OMD are associated with less response to levodopa;**

.because it competes with levo dopa for active transport to the CNS

: Kinetics of tolcapone and entacapone

.Penetrates the blood-brain barrier -1

.**Tolcapone** has a relatively **long duration** of action -2

.**Entacapone** requires **more** frequent **dosing** -3

Both drugs are **extensively metabolized** -3


.Eliminated in the **feces** and **urine**-5

.**Oral absorption** of both are readily and is **not influenced by food** -6


They are extensively **bound to plasma albumin**, with a limited volume-7
of distribution

A When peripheral dopamine decarboxylase activity is inhibited by *carbidopa*, a significant concentration of 3-O-methyldopa is formed, which competes with *levodopa* for active transport into the CNS.

B Inhibition of COMT by *entacapone* leads to decreased plasma concentrations of 3-O-methyldopa, increased central uptake of *levodopa*, and greater concentrations of brain dopamine.



Decreased metabolism
in GI tract and peripheral tissues



Decreased metabolism
in GI tract and peripheral tissues

Adverse effects

Dyskinesias, hallucinations and sleep disorders.1

.Diarrhea (peripheral effect in GIT) .2

Tolcapone may cause severe **liver damage.3**
(necrosis) there for should **monitor** hepatic
function

Postural hypotension, nausea, anorexia -4

:USE

indicated as an **adjunct** to levodopa and carbidopa
for the treatment of the signs and symptoms of
idiopathic Parkinson's disease

:Antimuscarinic Drugs - 6

Centrally acting antimuscarinic drugs used to help control the tremor and rigidity with little effect on bradykinesia. including

,Benzotropine

,Biperidin

,orphenadine

.Procyclidine

Trihexyphenidyl



:Mechanism of action

Decrease actions of cholinergic neurons in the .brain by blocking muscarinic receptors

.:Adverse effect

CNS effect: drowsiness, confusion, -1
.delusion, and hallucination

Peripheral effects: urine retention , dry -2
mouth, constipation, blurred vision ,
.....etc (**atropine like adverse effects**)

Note: Drugs that induce parkinsonism

A-Reversible

Metoclopramide-

Neuroleptic (Antipsychotic) bs they block Dopamine-receptor) like butyrophenones & phenothiazines or haloperidol

B-Irreversible

MPTP (1-methyl 4-phenyl 1,2,3,6- tetrahydropyridine) .which is a byproduct of meperidine analog

In pregnancy: levodopa, rasagiline, pramipexole, and ropinirole **alone** or in **combination** with each other may be considered **relatively safe** during pregnancy with **.Expected risks** should be considered

THANK YOU 2022

